Functional Analysis of Nuclear Receptor Variants

核受体变体的功能分析

基本信息

  • 批准号:
    8197094
  • 负责人:
  • 金额:
    $ 31.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-09-01 至 2013-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The constitutive androstane receptor (CAR, NR1I3) is a member of the nuclear receptor superfamily that is expressed primarily in the liver. CAR plays a key role in regulating all three phases of biotransformation, pathways that determine the fates of metabolism and toxicity associated with exposures to drugs, other xenobiotics, and endogenous substances such as bile acids, thyroid hormone, heme, and steroids. Due to the importance of this receptor system as a determinant of xenobiotic disposition in man, together with CAR's increasingly recognized role as a physiological regulator, it is imperative to fully characterize the biological processes directed by the human CAR proteome. Progress in the previous research program included the discovery of novel forms of CAR, CAR2 and CAR3; receptors generated through the use of alternative splicing mechanisms that result in the insertion of 4- and 5- amino acids, respectively, within the receptors' ligand binding domain. These receptors are expressed simultaneously with CAR in human livers, but possess highly unique functional attributes. Unlike CAR itself, the variant CARs are ligand-activated receptors, exhibit selective chemical activation profiles, and appear to differentially modulate target gene expression. We hypothesize that alternative splicing enhances the functional diversity of CAR molecules, resulting in overlapping, yet discriminating roles as xenobiotic sensors, driving the interplay of hepatic gene expression networks that in turn, provide critical integration signals directing human physiological responses to the chemical milieu. To test our hypotheses, a progression of three specific aims will be deployed that include: 1) the structural analysis of crystallized CAR proteins; 2) use of primary human hepatocyte culture models to enable receptor-driven transcriptional profiling, target gene interactions, and assessment of the dynamics of receptor intracellular localization; and, 3) humanized transgenic mouse investigations to analyze the transcriptional controls modulated by the receptors in vivo, and the phenotypic impact of receptor expression within a series of serum markers. We predict that the respective modulation of genomic programs and the resulting signaling circuitry controlled by the variant CARs have critical functional implications for human health, determining outcomes such as drug-drug interactions, drug and bile acid induced hepatotoxicity, carcinogen and steroid metabolism, and the regulation of lipid and energy homeostasis. The results of the proposed research will contribute important new advances and insights regarding the role of the CAR nuclear receptors as direct modulators of the dynamic gene regulatory networks that determine toxicological and physiological responses to both xenobiotic and endogenous substances. PUBLIC HEALTH RELEVANCE: In this research program, our studies will characterize the roles of a novel series of receptor proteins that interact with pharmaceuticals and environmental chemicals and function to regulate the liver's capacity to metabolize substances. These receptors are termed constitutive androstane receptors and are part of a battery of sensing proteins that exist with liver cells to assist in processing the nature of the cell's chemical environment so that it can better tune its ability to detoxify chemicals we are exposed to.
描述(由申请人提供):组成型雄烷受体(CAR,NR 1 I3)是主要在肝脏中表达的核受体超家族成员。CAR在调节生物转化的所有三个阶段中起关键作用,生物转化是决定与暴露于药物、其他外源性物质和内源性物质(如胆汁酸、甲状腺激素、血红素和类固醇)相关的代谢和毒性的命运的途径。由于该受体系统作为人类异生质处置的决定因素的重要性,以及CAR作为生理调节剂的作用日益被认可,因此必须充分表征由人CAR蛋白质组指导的生物过程。先前研究计划的进展包括发现新形式的CAR、CAR 2和CAR 3;通过使用选择性剪接机制产生的受体,该机制分别导致在受体的配体结合结构域内插入4个和5个氨基酸。这些受体在人类肝脏中与CAR同时表达,但具有高度独特的功能属性。与CAR本身不同,变体汽车是配体激活的受体,表现出选择性化学激活谱,并且似乎差异性地调节靶基因表达。我们假设选择性剪接增强了CAR分子的功能多样性,导致作为异生物质传感器的重叠但有区别的作用,驱动肝脏基因表达网络的相互作用,反过来,提供指导人类对化学环境的生理反应的关键整合信号。为了验证我们的假设,将部署三个具体目标的进展,包括:1)结晶CAR蛋白的结构分析; 2)使用原代人肝细胞培养模型以实现受体驱动的转录谱分析、靶基因相互作用和受体细胞内定位的动力学评估;和3)人源化转基因小鼠研究,以分析受体在体内调节的转录控制,以及受体表达在一系列血清标志物内的表型影响。我们预测,基因组程序的相应调节和由变体汽车控制的所得信号传导回路对人类健康具有关键的功能性影响,决定诸如药物-药物相互作用、药物和胆汁酸诱导的肝毒性、致癌物和类固醇代谢以及脂质和能量稳态的调节等结果。拟议研究的结果将有助于重要的新进展和见解,关于CAR核受体作为动态基因调控网络的直接调节剂的作用,这些动态基因调控网络决定了对外源性和内源性物质的毒理学和生理学反应。 公共卫生相关性:在这项研究计划中,我们的研究将描述一系列新的受体蛋白的作用,这些蛋白与药物和环境化学物质相互作用,并调节肝脏代谢物质的能力。这些受体被称为组成型雄烷受体,是与肝细胞一起存在的传感蛋白电池的一部分,以帮助处理细胞化学环境的性质,以便更好地调节其对我们暴露的化学物质进行解毒的能力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CURTIS J OMIECINSKI其他文献

CURTIS J OMIECINSKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CURTIS J OMIECINSKI', 18)}}的其他基金

Interindividual Variability in Human Microsomal Epoxide Hydrolase
人微粒体环氧化物水解酶的个体差异
  • 批准号:
    7655963
  • 财政年份:
    2009
  • 资助金额:
    $ 31.38万
  • 项目类别:
Interindividual Variability in Human Microsomal Epoxide Hydrolase
人微粒体环氧化物水解酶的个体差异
  • 批准号:
    8016009
  • 财政年份:
    2009
  • 资助金额:
    $ 31.38万
  • 项目类别:
Interindividual Variability in Human Microsomal Epoxide Hydrolase
人微粒体环氧化物水解酶的个体差异
  • 批准号:
    8217302
  • 财政年份:
    2009
  • 资助金额:
    $ 31.38万
  • 项目类别:
FUNCTIONAL ANALYSIS OF NUCLEAR RECEPTOR VARIANTS
核受体变体的功能分析
  • 批准号:
    6797326
  • 财政年份:
    2002
  • 资助金额:
    $ 31.38万
  • 项目类别:
FUNCTIONAL ANALYSIS OF NUCLEAR RECEPTOR VARIANTS
核受体变体的功能分析
  • 批准号:
    6943529
  • 财政年份:
    2002
  • 资助金额:
    $ 31.38万
  • 项目类别:
Functional Analysis of Nuclear Receptor Variants
核受体变体的功能分析
  • 批准号:
    8536555
  • 财政年份:
    2002
  • 资助金额:
    $ 31.38万
  • 项目类别:
Targeting Dynamics of CAR and PXR in the Mouse and Human Genomes
CAR 和 PXR 在小鼠和人类基因组中的靶向动态
  • 批准号:
    9021236
  • 财政年份:
    2002
  • 资助金额:
    $ 31.38万
  • 项目类别:
CORE--MOLECULAR BIOLOGY/BIOMARKER LABORATORY
核心--分子生物学/生物标志物实验室
  • 批准号:
    6577782
  • 财政年份:
    2002
  • 资助金额:
    $ 31.38万
  • 项目类别:
FUNCTIONAL ANALYSIS OF NUCLEAR RECEPTOR VARIANTS
核受体变体的功能分析
  • 批准号:
    6933713
  • 财政年份:
    2002
  • 资助金额:
    $ 31.38万
  • 项目类别:
Functional Analysis of Nuclear Receptor Variants
核受体变体的功能分析
  • 批准号:
    7786432
  • 财政年份:
    2002
  • 资助金额:
    $ 31.38万
  • 项目类别:

相似海外基金

Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
  • 批准号:
    488788
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
    Operating Grants
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
  • 批准号:
    10577186
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
  • 批准号:
    10717440
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
  • 批准号:
    10638347
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
  • 批准号:
    10749474
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
  • 批准号:
    10673458
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
  • 批准号:
    2884151
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
    Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
  • 批准号:
    10660668
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
  • 批准号:
    2239056
  • 财政年份:
    2023
  • 资助金额:
    $ 31.38万
  • 项目类别:
    Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
  • 批准号:
    468851650
  • 财政年份:
    2022
  • 资助金额:
    $ 31.38万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了